Search

Develop and pilot test a mobile health (mHealth) cognitive behavioral coping skills training and activity coaching protocol (HCT Symptoms and Steps) for hematopoietic stem cell transplant (HCT) patients. Two-phase, mixed methods study. HCT patients and healthcare providers. Phase I was patient (n = 5) and provider (n = 1) focus groups and user testing (N = 5) to develop the HCT Symptoms and Steps protocol. Phase II was a pilot randomized trial (N = 40) to evaluate feasibility, acceptability, and pre-to-post outcomes (e.g., physical disability, pain, fatigue, distress, physical activity, symptom self-efficacy) compared to an education control. Qualitative feedback on symptoms, recruitment strategies, coping skills, and mHealth components (e.g., Fitbit, mobile app) were integrated into the protocol. HCT Symptoms and Steps were feasible and acceptable. Pre-post changes suggest physical disability and activity improved while symptoms (e.g., fatigue, distress) decreased. HCT Symptoms and Steps have strong feasibility and acceptability and shows promise for benefits. Larger, fully-powered randomized trials are needed to examine intervention efficacy. HCT Symptoms and Steps may reduce physical disability and improve health outcomes post-transplant. NCT03859765 [ABSTRACT FROM AUTHOR]

This controlled comparison study evaluated objective and subjective cognitive function and their relationships with patient-reported symptoms (depression, fatigue, insomnia) in patients receiving tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and non-cancer controls. Patients with CML in chronic phase treated with the same oral TKI for ≥6 months (n = 90) and non-cancer controls (n = 87) completed a neurocognitive battery and self-report measures. Patients demonstrated worse overall neuropsychological performance (p =.05) and verbal memory (p =.02) compared to controls. Patients were not more likely to meet criteria for impaired cognitive performance compared to controls (ps>.26). Patients reported worse subjective global and domain-specific cognitive complaints and less satisfaction with cognitive function compared to controls (ps <.05). Patients also reported greater fatigue and insomnia symptoms (ps <.001). In both groups, greater fatigue, insomnia, and depressive symptoms were associated with worse subjective cognition (ps <.01). Longitudinal studies are needed to examine changes in cognitive function in patients before and during TKI treatment. [ABSTRACT FROM AUTHOR]

Background Trials of immune checkpoint inhibitors (ICIs) have published patient-reported quality of life (QOL), but the size and heterogeneity of this literature can make patient education difficult. This meta-analysis aimed to describe change in QOL and symptomatology in patients receiving ICIs for cancer. Methods Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, databases were searched through November 2019 for articles or abstracts of prospective, original studies reporting longitudinal QOL in adult cancer patients treated with ICIs. The prespecified primary outcomes were change in global QOL among patients treated with ICIs and difference in change since baseline in global QOL between patients treated with ICI vs non-ICI active treatment. Secondary outcomes included physical functioning and symptomatology. All statistical tests were 2-sided. Results Of 20 323 publications, 26 met inclusion criteria. Global QOL did not change over time in patients treated with ICIs (k = 26, n = 6974; P  =  .19). Larger improvements in global QOL was observed in patients receiving ICI vs non-ICI regimens (k = 16, ICI: n = 3588; non-ICI: n = 2948; P  <  .001). Physical functioning did not change in patients treated with ICIs (k = 14, n = 3169; P =.47); there were no differences in mean change between ICI vs non-ICI regimens (k = 11, n = 4630; P =.94). Regarding symptoms, appetite loss, insomnia, and pain severity decreased, but dyspnea severity increased in patients treated with ICIs (k = 14, n = 3243-3499; P <.001). Insomnia severity was higher in patients treated with ICIs than non-ICI regimens (k = 11, n = 4791; P  <  .001). Conclusions This study is among the first to quantitatively summarize QOL in patients treated with ICIs. Findings suggest ICI recipients report no change in global QOL and higher QOL than patients treated with non-ICI regimens. [ABSTRACT FROM AUTHOR]

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.anbehav.2006.10.006 Byline: Kelly M. Hyland, Tuan T. Cao, Alana M. Malechuk, Lee A. Lewis, Stanley S. Schneider Abstract: We investigated the effects of colony condition on the use of modulatory communication in social insects by examining vibration signal behaviour in established and newly founded colonies of the honeybee, Apis mellifera. Compared to the established colonies, the newly founded colonies had smaller population sizes, built more comb, devoted proportionately more comb space to brood rearing and less to food storage, gained weight, and had higher per capita rates of foraging. In conjunction with the different growth and foraging patterns, the newly founded colonies also had higher per capita vibration rates and slightly but significantly greater proportions of workers that produced the signal. Individual vibrators in the newly founded colonies performed signals on slightly but significantly more of the workers they contacted and focused their vibration activity more strongly on less active recipients than did vibrators in the established colonies. Vibrated recipients showed increased task performance compared to nonvibrated controls, suggesting that the signal increased individual labour rates in both colony types. However, the levels of task performance did not differ between newly founded and established colony recipients, suggesting that the degree to which workers responded to the signal was not altered by colony developmental state. Thus, the vibration signal may have helped to adjust worker activity to the resource and labour demands associated with nest founding primarily by activating larger proportions of the less active work force, rather than by increasing the individual work efforts of recipients in the newly founded colonies relative to those in established colonies. Author Affiliation: (a) Department of Entomology, North Carolina State University, U.S.A. (a ) Department of Ecology & Evolutionary Biology, University of Arizona, U.S.A. (a ) Department of Biology, Wake Forest University, U.S.A. (As.) Department of Biology, University of North Carolina at Charlotte, U.S.A. Article History: Received 1 June 2006; Revised 6 September 2006; Accepted 12 October 2006 Article Note: (miscellaneous) MS. number: A10459R

Background: Cognitive behavioral therapy for targeted-therapy related fatigue (CBT-TTF) has demonstrated preliminary efficacy in reducing fatigue in patients treated with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML).Purpose: The aim of the current analyses was to explore whether fatigue perpetuating factors (disturbed sleep/wake cycle, dysregulated activity patterns, maladaptive cognitions about fatigue and cancer, insufficient processing of cancer and treatment, inadequate social support and interactions, heightened fear of cancer progression) changed over time in patients receiving CBT-TTF, and whether the effect of CBT-TTF on fatigue was mediated by these factors.Methods: Secondary data analyses were conducted from a pilot randomized controlled trial. Patients with CML treated with a TKI who reported moderate to severe fatigue were randomized 2:1 to CBT-TTF delivered via FaceTime for iPad or a waitlist control condition (WLC). Self-report measures of fatigue and fatigue perpetuating factors were obtained before randomization and post-intervention (i.e., approximately 18 weeks later). Mixed model and mediation analyses using bootstrap methods were used.Results: A total of 36 participants (CBT-TTF n = 22, WLC n = 14) who had baseline and 18-week follow-up data and attended >5 sessions for CBT-TTF were included. Participants randomized to CBT-TTF reported improvements in activity (mental, physical, social, p's ≤ .023) and cognitions (helplessness, catastrophizing, focusing on symptoms, self-efficacy, p's ≤ .003) compared to WLC. Mental activity, social activity, self-efficacy, helplessness, and focusing on symptoms, as well as sleep and insufficient processing (avoidance) mediated the relationship between treatment group and fatigue.Conclusions: CBT-TTF appears to improve TKI-related fatigue in CML patients through changes in behavior (sleep, activity patterns) and cognitions about fatigue and cancer. A larger randomized controlled trial is warranted to confirm these findings. [ABSTRACT FROM AUTHOR]